BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9537	Companies
187817	Keywords
119775	Articles
100359	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 12/09/2025 at 09:10, 7 days 12 hours ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
BRIEF

published on 12/09/2025 at 09:10, 7 days 12 hours ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
PRESS RELEASE

published on 12/09/2025 at 09:05, 7 days 12 hours ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 15 days 12 hours ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
BRIEF

published on 12/01/2025 at 09:10, 15 days 12 hours ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs
PRESS RELEASE

published on 12/01/2025 at 09:05, 15 days 12 hours ago

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant
BRIEF

published on 11/20/2025 at 09:10, 26 days 12 hours ago

BioNxt obtient un brevet eurasien pour sa plateforme de cladribine sublinguale

Marché Mondial Maladies Auto-immunes Solutions BioNxt Cladribine Sublinguale Brevet Accordé
BRIEF

published on 11/20/2025 at 09:10, 26 days 12 hours ago

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine
PRESS RELEASE

published on 11/20/2025 at 09:05, 26 days 12 hours ago

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress

BioNxt Solutions Inc. Sublingual Delivery Eurasian Patent Pharmaceutical Markets Global IP Strategy
BRIEF

published on 11/04/2025 at 09:10, 1 month 12 days ago

BioNxt Receives European Patent Notification for Cladribine Thin-Film

Multiple Sclerosis Oral Therapies Cladribine European Patent BioNxt

Accesswire

Published on 12/16/2025 at 19:25, 2 hours 16 minutes ago

Cypher Metaverse Inc. Announces Signing of Definitive Agreement for Acquisition
Published on 12/16/2025 at 18:00, 3 hours 41 minutes ago

RTO SPA Terminated: Mumena Mushinge, Brian Chasala, Terra Metals Inc. and Terra Metals Limited Failed to Provide Necessary Due Diligence Information and Failed to File CSE Application
Published on 12/16/2025 at 14:30, 7 hours 11 minutes ago

Worksport Launches Rivian R1T Pickup Truck Compatible Cover, SOLIS Solar Tonneau
Published on 12/16/2025 at 14:00, 7 hours 41 minutes ago

QNX Embedded Technology Now Powering More Than 275 Million Vehicles on the Road
Published on 12/16/2025 at 14:00, 7 hours 41 minutes ago

Loop Industries and Ester Industries' India Joint Venture Awards Detailed Engineering Contract to Toyo for Infinite Loop(TM) India

View all ACCESSWIRE

EQS Group

Published on 12/16/2025 at 19:00, 2 hours 41 minutes ago

UV GERMI: COMMUNIQUE RELATIF AU DEPOT D’UN PROJET D’OFFRE PUBLIQUE DE RACHAT D’ACTIONS INITIÉE PAR UV GERMI PORTANT SUR 800 000 DE SES PROPRES ACTIONS EN VUE DE LA REDUCTION DE SON CAPITAL
Published on 12/16/2025 at 18:54, 2 hours 47 minutes ago

Fuller, Smith & Turner PLC:
Published on 12/16/2025 at 18:30, 3 hours 11 minutes ago

SIX Exchange Regulation approves delisting of u-blox registered shares and grants exemption from specific disclosure requirements
Published on 12/16/2025 at 18:23, 3 hours 18 minutes ago

Ouverture technologique et flexibilisation s'imposent
Published on 12/16/2025 at 17:52, 3 hours 49 minutes ago

POS-Transaction in Own Shares

Les Echos

Published on 12/16/2025 at 20:10, 1 hour 31 minutes ago

donation of shares of Seval, member of the Feuillet family concert
Published on 12/16/2025 at 20:10, 1 hour 31 minutes ago

Donation de titres de la société Seval, membre du concert familial Feuillet
Published on 12/16/2025 at 18:53, 2 hours 48 minutes ago

Number of shares and voting rights - November 2025 (In French only)
Published on 12/16/2025 at 18:53, 2 hours 48 minutes ago

Nombre total d'actions et droits de vote - novembre 2025
Published on 12/16/2025 at 18:10, 3 hours 31 minutes ago

Franchissement à la hausse du seuil statutaire de 2% par la société Amundi

View all LES ECHOS COMFI WIRE